MTAP encodes methylthioadenosine phosphorylase, an enzyme in the methionine salvage pathway that recycles methylthioadenosine to methionine. The gene resides on chromosome 9p21.3, adjacent to the ...

Celgene and Agios confirmed the initiation of a new anticancer drug development program focused on methylthioadenosine phosphorylase (MTAP)-deleted cancers as part of their potentially $1 billion ...

The incidence of both MTAP deletion and RAS mutations in pancreatic cancer is about 30%-40%, so inhibiting both pathways could be a promising approach to treatment, but it remains unclear whether ...

* Says Celgene will pay Agios an $8 million designation fee for MTAP pathway program * Agios Pharmaceuticals Inc - Celgene will have an opt-in right on program up through Phase 1 dose escalation for ...

­First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane ...

­Initiated monotherapy expansion cohorts with enrollment open for NSCLC and esophagogastric tumors with MTAP deletion Initiated combination dose escalation cohorts with enrollment open for ...

- Ivosidenib Has Potential to be a First-in-Class Therapy for Patients with R/R AML and an IDH1 mutation - - Company Also Announces FDA Clearance of Investigational New Drug Application (IND) for ...

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that Celgene Corporation ...

"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt, MD, ...